GT Biopharma Interest Expense 2011-2026 | GTBP

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense GT Biopharma

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
156 K	-	20 K	8 K	718 K	-3 M	-2.13 M	9.12 M	8.6 M	6.56 M	17 M	5.15 M	1.2 M	1.65 M	556 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
17 M	-3 M	3.26 M

Quarterly Interest Expense GT Biopharma

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	156 K	-	-	-	-27 K	27 K	-	216 K	1 K	212 K	-	107 K	36 K	8 K	-	32 K	-	696 K	-	931 K	4.66 M	638 K	-	560 K	479 K	454 K	-	1.12 M	3.92 M	2.93 M	-	3.77 M	1.18 M	3.52 M	-	1.54 M	1.6 M	1.65 M	-	1.72 M	849 K	7.44 M	-	3.26 M	168 K	197 K	-	215 K	215 K	531 K	-	65 K	1.17 M	74 K	-	117 K	180 K	168 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.44 M	-27 K	1.14 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Enlivex Therapeutics Ltd. ENLV	1.93 M	$ 0.83	-0.96 %	$ 37.9 M	Israel
Exelixis EXEL	-198 K	$ 46.83	-3.85 %	$ 12.7 B	USA
BioNTech SE BNTX	14.2 M	$ 93.78	-1.55 %	$ 27.2 B	Germany
Fortress Biotech FBIO	17.6 M	$ 2.48	-2.94 %	$ 69.2 M	USA
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.17	3.19 %	$ 3.67 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 3.14	-0.32 %	$ 653 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.66	9.25 %	$ 6.03 M	Israel
Genprex GNPX	38 K	$ 0.89	-0.2 %	$ 830 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 22.41	-7.3 %	$ 2.85 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
CRISPR Therapeutics AG CRSP	86.6 M	$ 53.95	-2.05 %	$ 4.85 B	Schweiz
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.63	-4.41 %	$ 434 M	Britain